Sorafenib induced hepatic encephalopathy.

Sidhu, S S; Agarwal, S; Goyal, O; Kishore, H; Sidhu, S

Sidhu, S S; Agarwal, S; Goyal, O; Kishore, H; Sidhu, S.

Affiliation

Sidhu SS; Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.
Agarwal S; Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.
Goyal O; Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.
Kishore H; Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.
Sidhu S; Himalayan institute of Medical Sciences, Swami Rama Himalayan University, Doiwala, Dehradun, Uttarkhand, India.

Acta Gastroenterol Belg ; 80(4): 537-538, 2017.

Article in En | MEDLINE | ID: mdl-29560652

Subject(s)

Antineoplastic Agents/adverse effects; Carcinoma, Hepatocellular/drug therapy; Hepatic Encephalopathy/chemically induced; Liver Neoplasms/drug therapy; Niacinamide/analogs & derivatives; Phenylurea Compounds/adverse effects; Carcinoma, Hepatocellular/surgery; Humans; Liver Neoplasms/surgery; Male; Middle Aged; Niacinamide/adverse effects; Recurrence; Sorafenib

Key words

Sorafenib; hepatic encephalopathy; hepatocellular carcinoma

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Phenylurea Compounds / Hepatic Encephalopathy / Niacinamide / Carcinoma, Hepatocellular / Liver Neoplasms / Antineoplastic Agents Limits: Humans / Male / Middle aged Language: En Journal: Acta Gastroenterol Belg Year: 2017 Document type: Article Affiliation country: India Country of publication: Belgium

Search on Google

Add to My VHL

XML

PubMed Links